The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Noncash financing expenses | - | 0 | 0 | 3,061 |
| Change in fair value of derivative instruments | - | 0 | 0 | 2,631 |
| Gain on sale of assets | - | 0 | 0 | 16 |
| Net loss | -6,946 | -5,713 | -4,423 | -12,250 |
| Depreciation and amortization | 96 | 145 | 77 | 223 |
| Stock-based compensation expense | 1,022 | 713 | 527 | 300 |
| Noncash interest expense | 17 | - | - | - |
| Accretion of discount on short-term investments | 21 | -10 | -3 | 22 |
| Operating lease right-of-use asset amortization | -40 | - | 9 | 44 |
| Grant receivable | 1,028 | -699 | - | 450 |
| Other assets | -146 | 1,398 | -635 | - |
| Other current assets | - | - | - | 265 |
| Accounts payable and accrued expenses | 489 | 688 | -1,127 | -5,181 |
| Change in operating lease liabilities | -13 | -12 | -9 | -45 |
| Deferred grant liability | - | - | 1,045 | - |
| Other liabilities | -13 | 159 | - | - |
| Net cash used in operating activities | -6,238 | -6,257 | -2,548 | -11,970 |
| Purchases of property and equipment | 818 | 30 | 27 | 10 |
| Proceeds from sale of property and equipment | - | 0 | 0 | 30 |
| Purchase of short-term investments | 9,701 | -1,715 | 3,312 | 7,756 |
| Redemption of short-term investments | 1,986 | -7,537 | 4,643 | 6,662 |
| Purchase of intangible assets | - | - | 7 | - |
| Proceeds from sales of short-term investments | - | 4,768 | - | - |
| Proceeds from sale of common stock, pre-funded warrants, and warrants | - | -1 | 926 | 15,001 |
| Payment of financing costs | - | 0 | 2,250 | - |
| Net cash (used in) provided by investing activities | -8,533 | -1,077 | 1,297 | -1,074 |
| Proceeds from issuance of notes payable and warrants | - | 0 | 0 | 3,738 |
| Repayment of notes payable | - | 0 | 0 | 3,703 |
| Proceeds from credit facility | 1,000 | 750 | - | - |
| Repayment of credit facility | 1,100 | 0 | 0 | 3,292 |
| Proceeds from exercise of series b warrants from may 2024 pipe | - | - | - | 882 |
| Proceeds from sale of common stock under lincoln park purchase agreement | - | 3,003 | 16,817 | 2,795 |
| Proceeds from underwritten public offering | 15,000 | - | - | - |
| Payment to investors pursuant to letter agreement | 4,502 | 949 | 2,293 | - |
| Offering costs for sale of common stock | 1,363 | 0 | 11 | 220 |
| Net cash provided by financing activities | 9,035 | 2,803 | 12,307 | 15,201 |
| Net change in cash and cash equivalents | -5,736 | -4,531 | 11,056 | 2,157 |
| Cash, restricted cash and cash equivalents at beginning of period | 8,758 | 13,289 | 76 | - |
| Cash, restricted cash and cash equivalents at end of period | 3,022 | 8,758 | 13,289 | - |
PLUS THERAPEUTICS, INC. (PSTV)
PLUS THERAPEUTICS, INC. (PSTV)